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Background: The co-existence of viral hepatitis caused by HBV and HCV become common causes of severe liver
complication and immunological impairment among HIV infected individuals. The aim of this study was to assess
the seroprevalence of HBV and HCV and their correlation with CD4 and liver enzyme levels among HAART naïve
HIV positive individuals.
Method: A Cross-sectional study was conducted from March-May, 2011 at University of Gondar Teaching Hospital,
Northwest Ethiopia. HBV and HCV serological tests and liver enzymes as well as CD4 T cell level determination were
assessed following the standard procedures. Socio-demographic data was collected by using structured
questionnaire. The data was entered and analyzed by using SPSS version 20.0 statistical software and p < 0.05 was
considered as statistically significant.
Result: Among 400 study participants, the overall prevalence of HIV-viral hepatitis co-infection was 42(11.7%). The
prevalence of HIV-HBV, HIV-HCV and HIV-HBV-HCV co-infections were 20(5.6%), 18(5.0%) and 4(1.1%) respectively.
Study participants who had HIV-HBV, HIV-HCV and HIV-HBV-HCV co-infection have relatively raised mean liver
enzyme levels (ALT, AST and ALP) than HIV mono-infected once. Individuals with HIV-HBV, HIV-HCV and HIV-HBV-
HCV co-infection also had a lower mean CD4 levels than HIV mono-infected study participants. The mean CD4
value in males was lower than females.
Conclusion: The prevalence of HBV and HCV was higher than reports from general population of the country.
Raised levels of liver enzymes and lowered mean CD4 counts were seen in HIV-HBV, HIV-HCV and HIV-HBV-HCV co-
infections. These findings underscore the importance of screening all HIV positive individuals before initiating
antiretroviral treatment.
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Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)
are the most common cause of chronic liver diseases
worldwide. The infection continues to have a severe and
invasive impact on the health of millions of people
around the world and the infection is often asymptom-
atic [1-4]. Due to similar routes of viral transmission [5],* Correspondence: yitayihlab@gmail.com
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The co-infection pattern of these viruses showed that
10.0% of the HIV-infected population estimated to have
chronic HBV infection and around a third estimated to
have chronic HCV infection worldwide [2,5]. However,
studies reported [6-9] that the rates of co-infection of
HIV with either HCV or HBV vary from region to re-
gion, study population and risk factors for HIV acquisi-
tion. A systematic review in 18 sub Saharan African
countries also showed that the prevalence of HBV andentral Ltd. This is an Open Access article distributed under the terms of the
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and 6.9%, respectively [10].
Despite the effective decline of the mortality and mor-
bidity rate from HIV/AIDS as the result of highly active
antiretroviral therapy (HAART), liver diseases due to
chronic HBV and HCV infections become a leading
cause of death. Although the direct impact of HCV upon
HIV disease progression remains controversial in many
reports [8,11-15], the complex interactions between
HIV-HBV/HCV co-infection and HAART are increas-
ingly apparent in HIV disease progression [16].
In HIV-HBV co-infections, HIV infection causes in-
creased rates of persistent HBV infection, increased cir-
rhosis and liver-related mortality and increased risk of
hepatocellular carcinoma at lower CD4T cell counts
[17]. Similarly in HIV-HCV co-infections, there is a
more rapid progress to cirrhosis, end-stage liver disease
and hepatocellular carcinoma [18].
The impact of HBV and HCV could not limited in
causing liver hepatotoxicity but also results in failure in
immunological recovery in HIV positive patients. For ex-
ample, a study in Tanzania reported slow rate of im-
munologic recovery after initiation of HAART treatment
and higher risk of hepatotoxicity among HIV/HBV and
HIV/HCV co-infected patients [19]. Thus the manage-
ment of HBV and HCV in HIV infection is complicated
and bring high burden in particular where HIV is ram-
pant. As the result, globally HIV, HBV and HCV become
the major public health concerns [20,21]. In some coun-
tries, screening of HIV-infected individuals for HBV and
HCV is highly recommended before initiation of anti-
viral treatment [22].
In Ethiopia, the seroprevalence of HBV and HCV
among HIV positive individuals is scarce except few re-
ports among blood donors and infection prone groups
[23-25]. In addition, there is no report about liver en-
zyme levels and CD4 count determination among HIV-
HBV and/or HIV-HCV co-infected patients. Therefore,
the aim of this study was to assess the seroprevalence of
HBV and HCV and CD4 cells as well as liver enzyme
levels among HIV positive individuals at University of
Gondar Teaching Hospital, Northwest Ethiopia.
Materials and methods
Study design, area, and period
A cross-sectional study was conducted from March to
May, 2011 at University of Gondar Teaching Hospital,
which is found in Gondar town, Northwest Ethiopia.
Source population and study participants
The source populations were all HIV positive individuals
who had access to be served at University of Gondar
Teaching Hospital. The study participants were all
HAART naïve HIV positive adult individuals who hadvisited ART clinics at Gondar University Hospital during
the study period. A total of 403 study participants were
enrolled by considering 95% confidence interval, 5%
margin of error, 50% proportion (since there is no previ-
ous estimation of HBV and HCV among HIV infected
individuals in the area) and 5% contingency. However, 2
(0.5%) of them had refused to participate and the other
1(0.2%) were excluded due to chronic alcoholism and
400(99.3%) HIV positive individuals were used for the
final analysis.
Inclusion and exclusion criteria
All ART naïve adult HIV positive individuals who visited
ART clinic for CD4 and liver enzyme level determina-
tions for their pre-ART follow up during the study
period were included. But individuals who were on ART
follow up and those ART naïve but who refused to give
informed consent were excluded from the study. Individ-
uals who have been vaccinated against HBV and those
who visited ART clinic and requested for laboratory in-
vestigation for the second and consequent follow up at
the time of the study period were also excluded from the
study to avoid duplication. Patients who had TB, mal-
aria, leishmaniasis, opportunistic infections (OIs), drug
induced hepatotoxicity and chronic alcoholism were
assessed and excluded as per the HIV management
guidelines of Ethiopia [26].
Data collection procedures
Socio-demographic information and other relevant pos-
sible risk factors of the study participants were collected
using structured and pre tested questionnaire by trained
nurses and physicians. Ten milliliter (10 ml) of veinous
blood was aseptically collected using plain and EDTA
vacutainer tube (5 ml in each tube) for the determin-
ation of HBV and HCV seroprevalence and CD4 and
liver enzyme levels from each study participants. The
blood specimen in the plain tube was centrifuged at
3000 RPM for 5 minutes to separate the serum and used
for determination of liver enzyme levels within one hour
of separation. The remaining serum kept in deep re-
frigerator (−40°C) until detection of HBV and HCV. The
second tube that contains whole blood was used for the
CD4 levels determination.
The collected sera were checked for the presence of
HBsAg using TULIP’S INSTANT (TULIP DIAGNOS-
TICS (P) LTD. 88/89, Phase II C, Verna Ind. Est., Verna,
Goa-403 722, INDIA) which have sensitivity and specifi-
city of 100%. Anti-HCV antibody was detected using
Flavicheck-HCV WB (TULIP DIAGNOSTICS (P) LTD.
88/89, Phase II C, Verna Ind. Est., Verna, Goa-403 722,
INDIA) following the manufacturer’s instructions. The
catalytic activities of the liver enzyme levels were ana-
lyzed by using clinical chemistry analyzer (Humastar 80)
Table 1 Socio-demographic characteristics of HIV positive
study participants at University of Gondar Teaching
Hospital, Northwest Ethiopia, 2011
Characteristics Male N (%) Female N (%) Total N (%)
Age group
18-29 21(16.4) 107(83.6) 128(32.0)
30-39 50(29.9) 117(70.1) 167(41.8)
40-49 40(51.3) 38(48.7) 78(19.5)
≥50 11(40.7) 16(59.3) 27(6.8)
Marital status
Single 27(36.0) 48(64.0) 75(18.8)
Married 76(38.0) 124(62.0) 200(50.0)
Divorced 17(20.7) 65(79.3) 82(20.5)
Widowed 2(4.7) 41(95.3) 43(10.7)
Religion
Christian 111(30.2) 256(69.8) 367(91.8)
Muslim 11(33.3) 22(66.7) 33(8.2)
Education
Illiterate 34(22.5) 117(77.5) 151(37.7)
Elementary 31(32.3) 65(67.7) 96(24.0)
High school 37(33.3) 74(66.7) 111(27.8)
Certificate and above 20(47.6) 22(52.4) 42(10.5)
Residence
Urban 103(30.7) 232(69.3) 335(83.7)
Rural 19(29.2) 46(70.8) 65(16.3)
Occupation
Civil servant 33(56.9) 25(43.1) 58(14.5)
Merchant 18(42.9) 24(57.1) 42(10.5)
Daily laborer 21(52.5) 39(97.5) 60(10.0)
Farmer 15(60.0) 10(40.0) 25(6.3)
House wife 114(100) 114(28.5)
Student 3(42.9) 4(57.1) 7(1.8)
Driver 8(80.0) 2(20.0) 10(2.5)
Commercial sex worker 5(100.0) 5(1.3)
No work 7(14.6) 41(85.4) 48(12.0)
Other 17(54.8) 16(51.6) 31(7.7)
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cytometry machine.
Quality control
The standard operational procedures were strictly
followed for the quality control issues. Both hepatitis B
and C kits were checked by using known HBsAg and
anti-HCV antibody positive and negative control
samples. Similarly the quality of both CD4 and liver
enzyme reagents were regularly monitored by running
control materials in each morning before the actual
work was done.
Data analysis
The data was entered and analyzed using SPSS Version
20.0 statistical software and the differences in propor-
tions was evaluated by Pearson’s Chi-square test (x2 test)
and P-value of less than 0.05 was considered as statis-
tical significant. Mean plus standard deviation with 95%
confidence interval (CI) was also used for continuous
variables and the difference in means was compared
with independent-sample t-test.
Ethical consideration
The study was conducted after obtaining ethical clear-
ance from ethical committee of Department of Medical
Microbiology, Immunology and Parasitology, University
of Gondar (University of Gondar, College of Medicine
and Health Sciences, Ref. No: V/D06/07/2011). Informed
consent was also obtained from each study participants.
Result
Socio-demographic characteristics
Among 400 study participants, 122(30.5%) were males
(mean age: 37 ± 9 years) and 278(69.5%) were females
(mean age: 32 ±9 years) with male to female ratio of
0.4:1. The lowest and the highest age of the study partic-
ipants were 18 and 70 years respectively. The median
age of the study participants was 32 years. Majority 167
(41.8%) of the study participants were in the age group
of 30–39 years old. Among the study groups, 151
(37.7%) were illiterate (Table 1).
Seroprevalence of HBVand HCV
The overall prevalence of viral hepatitis (HBV and HCV)
was 42(11.7%). The seroprevalence of HBV and HCV
were 20(5.6%) and 18(5.0%), respectively. Only 4(1.1%)
of HIV positive individuals showed triple (HIV-HBV-
HCV) infections.
HIV-HBV and HIV-HCV co-infection and sociodemographic
characteristics
Significantly higher prevalence of HIV-HBV co-infection
was observed in males 11(9.4%) compared to females 9(3.4%) (X2 = 5.714, P = 0.017). Although statistically non-
significant, higher 6(8.3%) (X2 = 3.083, P = 0.379) preva-
lence of HIV-HBV co-infection was observed in the age
group between 40–49 years. Individuals who were
widowed 4(9.8%) (X2 =3.681, P = 0.298) and those who
had better educational status (certificate, diploma and
above) 4(10.3%) (X2 = 2.602, P = 0.457) showed non-
significantly higher HIV-HBV positive rate. The preva-
lence of HIV-HBV co-infection in urban and rural
residences were 17(5.3%) and 3 (5.0%) respectively. Non-
statistically significant higher prevalence of HIV-HCV
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the age group of 40–49 years 5(7.0%), in rural residence
4(6.6%), in married 12(6.3%) and in the housewives 8
(7.2%). The co-existence of both HBV and HCV in
males and females were 2(1.8%) and 2(0.8%) (X2 = 0.786,
P = 0.375) respectively (Table 2).Table 2 Sociodemographic characteristics and their associatio
of Gondar Teaching Hospital, Northwest Ethiopia, 2011








18-29 118(95.9) 5(4.1) X2 = 3.083 118(96.7)
30-39 150(94.3) 9(5.7) P = 0.379 150(94.9)
40-49 66(91.7) 6(8.3) 66(93.0)
≥50 24(100) 0(0) 24(96.0)
Sex
Male 106 (90.6) 11(9.4) X2 = 5.714 106(97.2)
Female 252(96.6) 9(3.4) P = 0.017 252(94.4)
Residence
Urban 301(94.7) 17(5.3) X2 = 0.12 301(95.6)
Rural 57(95.0) 3(5.0) P = 0.913 57(93.4)
Marital status
Single 72(96.0) 3(4.0) X2 = 3.681 72(100.0)
Married 178(96.2) 7(3.8) P = 0.298 178(93.7)
Divorced 71(92.2) 6(7.8) 71(94.7)
Widowed 37(90.2) 4(9.8) 37(94.9)
Religion
Christian 327(94.5) 19(5.5) X2 = 0.327 327(94.8)
Muslim 31(96.9) 1(3.1) P = 0.567 31(100.0)
Education
Illiterate 133(94.3) 8(5.7) X2 = 2.602 133(95.0)
Elementary 89(95.7) 4(4.3) P = 0.457 89(96.7)
High school 101(96.2) 4(3.8) 101(94.4)
Certificate & above 35(89.7) 4(10.3) 35(94.6)
Occupation
Civil servant 49(89.1) 6(10.9) X2 = 12.352 49(96.1)
Merchant 37(90.2) 4(9.8) P = 0.194 37(97.4)
Daily laborer 54(91.5) 5(8.5) 54(98.2)
Farmer 22(95.7) 1(4.3) 22(95.7)
House wife 103(99.0) 1(1.0) 103(92.8)
Student 7(100.0) 0(0.0) 7(100.0)
Driver 9(90.0) 1(10.0) 9(100.0)
Com. sex worker 4(100.0) 0(0.0) 4(100.0)
No work 44(97.8) 1(2.2) 44(93.6)
Other 29(96.7) 1(3.3) 29(93.5)Liver enzyme levels and mean CD4 count in HIV/HBV,
HIV/HCV and HBV/HCV/HIV co-infection
The mean serum levels; ALT, AST, and ALP in HIV
mono-infected study participants were 25 international
units (IU), 27 IU and 243 IU respectively. However, in









4(3.3) X2 = 1.461 118(99.2) 1(0.8) X2 = 12.169
8(5.1) P = 0.691 150(100.0) 0(0.0) P = 0.007
5(7.0) 66(98.5) 1(1.5)
1(4.0) 24(92.3) 2(7.7)
3(2.8) X2 = 1.395 106(98.2) 2(1.8) X2 = 0.786
15(5.6) P = 0.238 252(99.2) 2(0.8) P = 0.375
14(4.4) X2 = 0.501 301(99.0) 3(1.0) X2 = 0.242
4(6.6) P = 0.479 57(98.3) 1(1.7) P = 0.623
0(0.0) X2 = 4.653 72(100.0) 0(0.0) X2 = 1.777
12(6.3) P = 0.199 178(98.3) 3(1.7) P = 0.620
4(5.3) 71(98.6) 1(1.4)
2(5.1) 37(100.0) 0(0.0)
18(5.2) X2 = 1.699 327(99.1) 3(0.9) X2 = 1.311
0(0.0) P = 0.192 31(96.9) 1(3.1) P = 0.252
7(5.0) X2 = 0.672 133(97.8) 3(2.2) X2 = 4.553
3(3.3) P = 0.880 89(100.0) 0(0.0) P = 0.208
6(5.6) 101(100.0) 0(0.0)
2(5.4) 35(97.2) 1(2.8)
2(3.9) X2 = 4.427 49(98.0) 1(2.0) X2 = 5.695









Wondimeneh et al. Virology Journal 2013, 10:171 Page 5 of 8
http://www.virologyj.com/content/10/1/171ALT, AST and ALP were non-significantly raised (29 IU,
31 IU and 262 IU, respectively). Similarly, in HIV-HCV
co-infected study participants, the mean levels of ALT,
AST and ALP were 27 IU, 32 IU, and 290 IU respect-
ively. Statistically non-significant raised mean serum
ALT, AST and ALP were found in HIV-HBV-HCV triple
infected study participants (Table 3).
The mean CD4 count of HIV mono-infection was
288cells/mm3. However, in HIV-HBV, HIV-HCV and
HIV-HBV-HCV co-infections, the mean CD4 count were
250 cells/mm3, 274 cells/mm3 and 125 cells/mm3 re-
spectively. However, the difference was not statistically
significant (Table 3). The CD4 value in females was
higher than males (299 ± 197 vs 249 ± 152). Males study
participants who had both HBV and HCV have the low-
est mean CD4 count. The highest and lowest mean CD4
values were observed in the age groups of 18–29 and
≥50 years respectively (Table 4).
Discussion
This study investigated the seroprevalence of HBV and
HCV among HIV positive study participants and tried to
assess levels of liver enzymes and CD4 count for HIV
mono infected, HIV-HBV and HIV-HCV co-infected and
HIV-HBV-HCV triple infected individuals. The overall
prevalence (11.7%) of hepatitis (both HBV and HCV)
among the study participants was very high. In this
study, HIV-HBV co-infection rate was 5.6% which is
more or less comparable with 7.1% prevalence [24]
among blood donors in the same hospital. However, the
present prevalence was lower as compared to studies
reported in Nigeria (9.2%) [27], Ethiopia (10.9%) [23]
and Malawi (20.4%) [28]. In the present study, the preva-
lence of HIV-HBV co-infection was higher in males than
females (9.4%% vs 3.4%) which are in line with some
other reports [29-31]. Generally, as several studies
reported and anticipated in different parts of the world,Table 3 Mean CD4 and liver enzyme levels and their associat
Gondar Teaching Hospital, Northwest Ethiopia, 2011
Immunological and liver biomarkers HIV alone HIV/HBV P-value
CD4 mean ± SD 288 ± 190 250 0.375
Normal value 500-1300 500-1300
ALT mean ± SD 25 ± 21 29 ± 18 0.356
Normal value 0-37 0-37
Abnormal High (%) 12.3% 20%
AST mean ± SD 27 ± 19 31 ± 18 0.419
Normal value 0-34 0-34
Abnormal High (%) 20.1% 25%
ALP mean ± SD 243 ± 130 262 ± 118 0.515
Normal value 72-306 72-306
Abnormal High (%) 19.6% 15%such co-infection differences could be due to differences
in geographic regions, types of risk groups and the
means of exposures involved [26,27,32-35].
The seroprevalence rates of HIV-HCV co-infection in
this study was 5.0% which is almost comparable with the
studies which were done in Nigeria (5.8%), Malawi (5.0%),
Burkina Faso (4.8%) and Senegal (8.0%) [27,28,36,37]. How-
ever, the epidemiological survey of HCV in Ethiopia
showed variation from 2-3% in the general population in
early 1990s [38-40] and recently, the co-infection rates of
HIV-HCV ranges from 3.6-13.3% in different reports
[24,25,41-45]. The reasons for the HCV variation both in
HIV infected individuals and the general population could
share the factors responsible HBV prevalence variations
discussed above.
The seroprevalence of HIV-HBV-HCV triple infection
in this study was 1.1%, which is more or less comparable
to reports from Senegal (0.5%), Kenya (0.26%), Nigeria
(1.5%) and Egypt (0.44%) [37,46,47]. However, higher
prevalence of HCV-HBV-HIV triple co-infection was
reported in Argentina (9.5%) and Iran (9.2%) [48,49]. For
such variations, risk factors which accounts for HBV and
HIV prevalence difference might work for the triple
infection.
Despite absence of statistical significance difference in
the mean levels of the liver enzymes between HIV-mono-
infected and HIV-viral hepatitis co-infected individuals,
raised ALT, AST and ALP were found in HIV-HBV, HIV-
HCV and HIV-HBV-HCV co-infected individuals. How-
ever, in a study which was conducted in South Africa, 70%
of HIV-HBV and HIV-HCV co-infected study participants
had significantly elevated AST and ALT, 56% of them had
elevated ALP [35]. Similarly, significantly raised ALT was
found in 14% of HIV/HBV co-infections and 20% in HIV-
HCV co-infected patients in India [50]. These liver en-
zyme levels difference between different studies may be
due to difference in study design, duration of the viralion with HBV and HCV co-infection at University of
HIV alone HIV/HCV P-value HIV alone HIV/HBV/HCV P-value
288 ± 190 274 ± 138 0.754 288 ± 190 125 ± 96 0.087
500-1300 500-1300 500-1300 500-1300
25 ± 21 27 ± 17 0.472 25 ± 21 39 ± 6 0.170
0-37 0-37 0-37 0-37
12.3% 22.2% 12.3% 50%
27 ± 19 32 ± 17 0.339 27 ± 19 33 ± 15 0.587
0-34 0-34 0-34 0-34
20.1% 27.8% 20.1% 50%
243 ± 130 290 ± 127 0.135 243 ± 130 332 ± 228 0.176
72-306 72-306 72-306 72-306
19.6% 33.3% 19.6% 50%
Table 4 Mean CD4 values in relation to gender and different age categories at University of Gondar Teaching Hospital,
Northwest Ethiopia, 2011
Variables Mean CD4 count
HIV alone HIV-HBV HIV-HCV HIV-HBV-HCV Over all
Gender
Male 256 ±155 197 ± 113 334 ± 133 75 ± 30 249 ± 152
Female 302 ± 201 314 ± 188 262 ± 140 176 ± 129 299 ± 197
Age categories
18-29 338 ± 223 383 ± 201 328 + 151 84 ± 0 337 ± 219
30-39 261 ± 151 169 ± 108 241 + 128 255 ± 149
40-49 292 ± 203 260 ± 121 286 + 173 53 ± 0 286 ± 196
≥50 203 ± 135 260 +0 182 ± 121 204 ± 129
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having chronic alcoholism or other drug induced hepato-
toxicity. In addition, HIV can also infect the hepatic or
kupffer cells [51] that may farther contributes for the de-
velopment of liver fibrosis and raised liver enzyme levels.
However, the magnitude of the complication of the liver
may be worse if the HIV positive patients co-infected with
HBV and HCV as indicated in the above.
In the present study, there is no statistically significant
CD4 count mean difference between HIV mono-infected,
HIV-HBV and HIV- HCV co-infected study participants.
However, study participants who had HIV-HBV co-
infection in this study have the mean CD4 count (250
cells/mm3) which was incomparable with mean CD4
count of 141.6 cells/mm3 and 121 cells/mm3 in the studies
which were conducted in South Africa and Nigeria re-
spectively [35,46]. These controversial results may be due
to the differences in the immune status of the individual
who have been participated in the study or it may be due to
the viral hepatitis. In individuals who have both HIV and
HBV infections, there may be high HIV and HBV viral rep-
lication that may farther contribute for the impairment of
the immune system of the patients.
In this study, the mean CD4 count (274 cells/mm3)
was found in HIV-HCV co-infected study participants
which is comparable with a mean CD4 count of 260
cells/mm3 and 288.6 cells/mm3 that were reported in
Nigerian and Indian studies respectively [46,50]. Such
high values of mean CD4 count in HIV-HCV co-infected
study participants than study participants who had HIV-
HBV co-infections were unclear. However, HIV-HCV
co-infected study participants have relatively lower mean
CD4 values than HIV mono-infected study participants.
This low CD4 count in HIV-HCV co-infected may be as-
sociated with an increased HIV and HCV replication,
reflecting the immunosuppressed state.
Among HIV-HBV-HCV infected individuals, the mean
CD4 count was 125cells/mm3. This CD4 levels is com-
parable with the mean CD4 count of 116/mm3 whichwas reported in India [50]. Similarly in a study which
was done in Nigeria, HIV-HBV-HCV infected individ-
uals had the mean CD4 count of 106 cells/mm3 [46].
However, all of these results showed the mean CD4
count of less than 200 cells/mm3. This could be due to
the fact that the presence of both HBV and HCV in HIV
positive individuals may highly contribute for the im-
pairment of the immune system of an individual that
may also further lead the person for the development of
advanced HIV diseases. In addition, there is also inverse
relationship between CD4 values and HIV diseases pro-
gression. However, the impact of viral hepatitis on the
immune system and liver enzymes needs farther studies
in both on HAART and HAART naïve HIV positive
patients.
In the present study, there was also difference on the
mean CD4 values in relation to gender. The mean CD4
value in the males was lower than females (249 cells/mm3
vs 299 cells/mm3). Similar findings were reported in
studies which have been conducted in Nigeria [52] and
Uganda [53]. Male study participants who had both
HBV and HCV had also the lowest mean CD4 values.
This lower CD4 count in males may be associated with
their daily activities. In addition, males are mostly more
muscular and may not be ready to accept their HIV,
HBV and/or HCV results and they may develop mental
stress that farther contribute for the impairment of their
immune system or lower CD4 count. Farther more, males
may spend most of their time with hard works for a long
period of time and this may contribute for lower CD4
count. We have also analyzed the mean CD4 values in
different age categories and the lowest mean CD4 values
was observed in the age groups of 50 years and above.
As age increases, there may be impairment of the immune
system of the individuals specially HIV positive patients
and older age groups may have severed HIV diseases
progression than younger once.
In conclusion, the prevalence of viral hepatitis (HBV,
HCV) among HIV positive individuals was higher than
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http://www.virologyj.com/content/10/1/171the prevalence of the respective viruses in the general
population. Thus screening of HBV and HCV before ini-
tiation of antiretroviral treatment is mandatory for strict
monitoring and a regular evaluation of liver enzyme
levels and CD4 status in order to minimize the compli-
cation of the liver and for effective HIV treatment.
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